Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ren Lang

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Gut|July 3, 2026
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation studyYan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|September 29, 2021
Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective studyRen-Yi Su, Sun-Bin Ling, Qiao-Nan Shan, et al.
Hepatobiliary Surgery and Nutrition|December 13, 2024
Chinese guidelines for minimally invasive donor hepatectomy in living donor liver transplantation (2024 edition)Xi Xu, Tao Lv, Gang Xu, et al.
Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Gut|July 3, 2026
Glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors after liver resection for hepatocellular carcinoma in patients with type 2 diabetes: a target trial emulation studyYan-Jun Xiang, Zong-Han Liu, Jin-Kai Feng, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|September 29, 2021
Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective studyRen-Yi Su, Sun-Bin Ling, Qiao-Nan Shan, et al.
Hepatobiliary Surgery and Nutrition|December 13, 2024
Chinese guidelines for minimally invasive donor hepatectomy in living donor liver transplantation (2024 edition)Xi Xu, Tao Lv, Gang Xu, et al.
Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.
Pageof 13